Rabbit Recombinant Monoclonal FCRL5 antibody. Carrier free. Suitable for sELISA and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
| sELISA | |
|---|---|
| Human | Tested |
| Species | Dilution info | Notes |
|---|---|---|
Species Human | Dilution info - | Notes - |
Plays an important role in B-cell response to antigen that acts both as a negative or positive coreceptor. Inhibits B-cell receptor (BCR) signaling in the absence of CR2 stimulation but engagement with CR2 and the BCR lead to a superior calcium response compared to CR2 and BCR costimulation (PubMed:30107486). May be involved in B-cell development and differentiation in peripheral lymphoid organs and may be useful markers of B-cell stages. May have an immunoregulatory role in marginal zone B-cells. May play a role in fertilization (By similarity).
CD307e, FCRH5, IRTA2, UNQ503/PRO820, FCRL5, Fc receptor-like protein 5, FcR-like protein 5, FcRL5, BXMAS1, Fc receptor homolog 5, Immune receptor translocation-associated protein 2, FcRH5
Rabbit Recombinant Monoclonal FCRL5 antibody. Carrier free. Suitable for sELISA and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: 100% PBS
The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Please note that the range provided for this antibody is only an estimation based on the performance of the product using the recommended antibody pair. Performance of the antibody pair will depend on the specific characteristics of your assay. We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibody in your assay.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
The FCRL5 also known as CD307 or Fc receptor-like 5 is a protein predominantly expressed on the surface of B cells and plasma cells. This protein weighs approximately 98 kDa. FCRL5 features structural similarities to classical Fc receptors suggesting a role in immune responses. Its expression is tightly regulated throughout B cell development and has been detected in lymphoid tissues with higher levels reported in bone marrow and secondary lymphoid organs.
FCRL5 modulates the immune system by influencing B cell activation and differentiation. It participates in the formation of immune complexes playing a dual role in both promoting and inhibiting immune responses depending on the surrounding conditions. This regulatory function suggests that FCRL5 can adjust immune system activities to maintain homeostasis. It acts independently and might form complexes with other immune regulatory proteins to fine-tune B cell responses.
FCRL5 plays a role in the adaptive immune response and is associated with the B cell receptor (BCR) signaling pathway. It interacts with proteins such as CD19 and CD79 influencing downstream signaling cascades critical for B cell maturation and effector functions. The interaction of FCRL5 with these pathways highlights its importance in modulating signal transduction that leads to cytokine production and antibody generation.
FCRL5 has been implicated in the pathogenesis of autoimmune diseases and certain hematological cancers such as chronic lymphocytic leukemia (CLL). Abnormal expression or mutations of FCRL5 can dysregulate normal B cell function contributing to disease development. In CLL FCRL5 potentially interacts with proteins like leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) influencing cancer cell survival and proliferation making it a target for therapeutic intervention and a potential biomarker for disease progression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com